Measles virus, live attenuated
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2006
- First approval year
- 2006
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Measles virus, live attenuated
- measles virus live attenuated component of m m rvaxpro
- measles virus live attenuated component of proquad
- Measles virus, live attenuated component of m-m-rvaxpro
- Measles virus, live attenuated component of proquad
- measles virus live attenuated
- Measles virus, live attenuated
- ChEMBL ID
- CHEMBL6068354
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Measles
- Highest recorded phase
- 4
- Condition identifier
- EFO:1002025
- Subject identifier
- D008457
- Condition identifier
- EFO_0006509
- Condition identifier
- EFO_0007383
- Condition identifier
- EFO_1002025
- Condition identifier
- EFO_1002026
- Condition identifier
- MONDO_0005608
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (79)
- A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
- A Second Dose of Measles Vaccine (MV) in the Second Year of Life
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
- A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
- Additional Measles Vaccine at 4 Months of Age
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
- Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
- Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
- CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
- Early Two-dose Measles Vaccination Trial